Find the right fit for you - faster
Get tailored insights about working at Telik in one quick step.
Telik Snapshot
Go Telik on the mountain: Telik discovers new drugs, focusing mainly on treatments for cancer. The company uses its proprietary Target-Related Affinity Profiling (TRAP) technology to identify potential drug compounds by analyzing the way they interact with proteins. Lead drug candidate Telcyta targets chemotherapy-resistant tumors and is undergoing clinical trials for several kinds of cancer, including ovarian and non-small cell lung cancers. Another candidate, Telintra, may treat blood disorders, including neutropenia and myelodysplastic syndrome. Telik has a host of other anticancer compounds at earlier stages of development.
